EUCTR2011-002833-20-GB
Active, not recruiting
Phase 1
Prospective study of 18F-RGD PET-CT in assessment of response to antiangiogenic treatment in patients with renal cancer and comparison with perfusion CT - RGD-PET in Kidney Cancer angiogenesis
ConditionsPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Primary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.
- Sponsor
- Oxford University Hospitals NHS Trust
- Enrollment
- 10
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A patient will be eligible for inclusion in this study if all of the following criteria apply:
- •1Patients should have advanced or metastatic RCC confirmed by histological diagnosis
- •2Patients considered suitable for therapy with TKI according to responsible clinician
- •3Measurable tumour according to RECIST v1\.1 criteria
- •4Standard staging CT scan performed within 28 days of first research scan
- •5The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment
- •6Age \=18 years
- •7Adequate renal function (creatinine \<1\.25xULN)
- •8Patient is able to tolerate and comply with scanning procedure
- •9Patient is not lactating or pregnant
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165
Unknown
Early Phase 1
18F-FDG PET/CT for IgG4-Related DiseaseAutoimmune DiseaseNCT01665196Peking Union Medical College Hospital100
Not yet recruiting
Not Applicable
To study the role of FDG PET-CT in patients with lower back spinal pain for localization of active site generating pain and causing pain symptoms.CTRI/2022/09/046021ot applicable
Completed
Not Applicable
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.NL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50
Terminated
Phase 2
RGD-PET-CT in Cancer AngiogenesisCarcinoma, Renal CellNCT01492192Oxford University Hospitals NHS Trust10